<DOC>
	<DOCNO>NCT00938717</DOCNO>
	<brief_summary>The purpose study determine safety efficacy linaclotide administer patient Irritable Bowel Syndrome Constipation ( IBS-C ) .</brief_summary>
	<brief_title>Trial Linaclotide Patients With Irritable Bowel Syndrome With Constipation ( IBS-C )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patient complete colonoscopy accord AGA criterion , clinically significant finding Patient successfully complete protocol procedure ( clinically significant finding ) : physical exam , 12lead ECG , clinical laboratory test Patient meet protocol criterion diagnosis IBSC Patient demonstrate continued IBSC Pretreatment Period Patient compliant IVRS Patient history loose watery stool Patient symptom diagnose medical condition may contribute abdominal pain Patient structural abnormality gastrointestinal ( GI ) tract disease condition affect GI motility Patient protocolexcluded clinically significant medical surgical history could confound study assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>IBS</keyword>
</DOC>